benserazide has been researched along with Colonic Neoplasms in 2 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Colonic Neoplasms: Tumors or cancer of the COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Benserazide (Benz), was identified as a selective HK2 inhibitor, could specifically bind to HK2 and significantly inhibit HK2 enzymatic activity in vitro." | 1.46 | Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. ( Chen, L; Gao, S; Li, H; Li, W; Li, Z; Min, Q; Sun, W; Wu, S; Xiang, G; Yang, M; Zheng, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W | 1 |
| Zheng, M | 1 |
| Wu, S | 1 |
| Gao, S | 1 |
| Yang, M | 1 |
| Li, Z | 1 |
| Min, Q | 1 |
| Sun, W | 1 |
| Chen, L | 1 |
| Xiang, G | 1 |
| Li, H | 1 |
| Vieira-Coelho, MA | 1 |
| Soares-Da-Silva, P | 1 |
2 other studies available for benserazide and Colonic Neoplasms
| Article | Year |
|---|---|
Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2.
Topics: Animals; Antineoplastic Agents; Benserazide; Cell Line; Cell Proliferation; Cell Survival; Chloroceb | 2017 |
Uptake and intracellular fate of L-DOPA in a human intestinal epithelial cell line: Caco-2.
Topics: Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Biological Transport; Caco-2 Cells; Chromatograph | 1998 |